Profile of erlotinib and its potential in the treatment of advanced ovarian carcinoma

References

• MongaMCarmichaelJAShelleyWESurgery without adjuvant chemotherapy for early epithelial ovarian carcinoma after comprehensive surgical stagingGynecol Oncol19914331951971752486
   PubMed Web of Science ®Google Scholar
• VermorkenJBPecorelliSClinical trials in patients with epithelial ovarian cancer: past, present and futureEur J Surg Oncol19962254554668903485
   PubMed Web of Science ®Google Scholar
• McGuireWPHoskinsWJBradyMFCyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancerN Engl J Med19963341167494563
   PubMed Web of Science ®Google Scholar
• PiccartMJBertelsenKJamesKRandomized Intergroup trial of cisplatin–paclitaxel versus cisplatin–cyclophosphamide in women with advanced epithelial ovarian cancer: three year resultsJ Natl Cancer Inst200092969970810793106
   PubMed Web of Science ®Google Scholar
• du BoisALuckHJBauknechtTFirst-line chemotherapy with epirubicin, paclitaxel, and carboplatin for advanced ovarian cancer: a phase I/II study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study GroupJ Clin Oncol1999171465110458217
   PubMed Web of Science ®Google Scholar
• OzolsRFBundyBNGreerBEPhase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group studyJ Clin Oncol200321173194320012860964
   PubMed Web of Science ®Google Scholar
• Fung-Kee-FungMOliverTElitLOzaAHirteHWBrysonPOptimal chemotherapy treatment for women with recurrent ovarian cancerCurr Oncol200714519520817938703
   PubMedGoogle Scholar
• WoodburnJRThe epidermal growth factor receptor and its inhibition in cancer therapyPharmacol Ther1999822–324125010454201
   PubMed Web of Science ®Google Scholar
• YardenYThe EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunitiesEur J Cancer200137 Suppl 4S3S811597398
   PubMed Web of Science ®Google Scholar
• PrenzelNFischerOMStreitSHartSUllrichAThe epidermal growth factor receptor family as a central element for cellular signal transduction and diversificationEndocr Relat Cancer200181113111350724
   PubMed Web of Science ®Google Scholar
• ZaczekABrandtBBielawskiKPThe diverse signaling network of EGFR, HER2, HER3 and HER4 tyrosine kinase receptors and the consequences for therapeutic approachesHistol Histopathol20052031005101515944951
   PubMed Web of Science ®Google Scholar
• ArteagaCTargeting HER1/EGFR: a molecular approach to cancer therapySemin Oncol2003303 Suppl 7314
   Web of Science ®Google Scholar
• BuettnerRMoraLBJoveRActivated STAT signaling in human tumors provides novel molecular targets for therapeutic interventionClin Cancer Res20028494595411948098
   PubMed Web of Science ®Google Scholar
• CitriAYardenYEGF-ERBB signalling: towards the systems levelNat Rev Mol Cell Biol20067750551616829981
   PubMed Web of Science ®Google Scholar
• AdamsTEMcKernNMWardCWSignalling by the type 1 insulin-like growth factor receptor: interplay with the epidermal growth factor receptorGrowth Factors2004222899515253384
   PubMed Web of Science ®Google Scholar
• JonesHEGeeJMWHutchesonIRKnowldenJMBarrowDNicholsonRIGrowth factor receptor interplay and resistance in cancerEndocr Rel Cancer200613 Suppl 1S45S51
   Web of Science ®Google Scholar
• QiuLZhouCSunYCrosstalk between EGFR and TrkB enhances ovarian cancer cell migration and proliferationInt J Oncol20062941003101116964397
   PubMed Web of Science ®Google Scholar
• GschwindAZwickEPrenzelNLesererMUllrichACell communication networks: epidermal growth factor receptor transactivation as the paradigm for interreceptor signal transmissionOncogene200120131594160011313906
   PubMed Web of Science ®Google Scholar
• ShidaDKitayamaJMoriKWatanabeTNagawaHTransactivation of epidermal growth factor receptor is involved in leptin-induced activation of Janus-activated kinase 2 and extracellular signal-regulated kinase 1/2 in human gastric cancer cellsCancer Res200565209159916316230373
   PubMed Web of Science ®Google Scholar
• AndlCDRustgiAKNo one-way street: crosstalk between E-cadherin and receptor tyrosine kinase (RTK) signaling: a mechanism to regulate RTK activityCancer Biol Ther200541283115662113
   PubMed Web of Science ®Google Scholar
• CabodiSMoroLBergattoEIntegrin regulation of epidermal growth factor (EGF) receptor and of EGF dependent responsesBiochem Soc Trans200432343844215157155
   PubMed Web of Science ®Google Scholar
• RiedemannJTakiguchiMSohailMMacaulayVMThe EGF receptor interacts with the type 1 IGF receptor and regulates its stabilityBiochem Biophys Res Commun2007355370771417307140
   PubMed Web of Science ®Google Scholar
• HurEMParkYSLeeBDSensitization of epidermal growth factor-induced signaling by bradykinin is mediated by c-Src: implications for a role of lipid microdomainsJ Biol Chem200427975852586014630916
   PubMed Web of Science ®Google Scholar
• ZhangQThomasSMLuiVWPhosphorylation of TNF-α converting enzyme by gastrin-releasing peptide induces amphiregulin release and EGF receptor activationProc Natl Acad Sci USA2006103186901690616641105
   PubMed Web of Science ®Google Scholar
• MiyamotoSYagiHYotsumotoFKawarabayashiTMekadaEHeparin-binding epidermal growth factor-like growth factor as a novel targeting molecule for cancer therapyCancer Sci200697534134716630129
   PubMed Web of Science ®Google Scholar
• YuSMurphMMLuYLysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cellsJ Natl Cancer Inst2008100221630164219001604
   PubMedGoogle Scholar
• MillsGBMoolenaarWHThe emerging role of lysophosphatidic acid in cancerNat Rev Cancer20033858259112894246
   PubMed Web of Science ®Google Scholar
• FangXSchummerMMaoMLysophosphatidic acid is a bioactive mediator in ovarian cancerBiochim Biophys Acta200215821–325726412069836
   PubMed Web of Science ®Google Scholar
• YuXLiuLCaiBHeYWanXSuppression of anoikis by the neurotrophic receptor TrkB in human ovarian cancerCancer Sci200829354355218201274
   PubMed Web of Science ®Google Scholar
• MiettinenPJBergerJEMenesesJEpithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptorNature199537665383373417630400
   PubMed Web of Science ®Google Scholar
• SibiliaMWagnerEFStrain-dependent epithelial defects in mice lacking the EGF receptorScience199526952212342387618085
   PubMed Web of Science ®Google Scholar
• SibiliaMKroismayrRLichtenbergerBMNatarajanAHeckingMHolcmannMThe epidermal growth factor receptor: from development to tumorigenesisDifferentiation200775977078717999740
   PubMed Web of Science ®Google Scholar
• HsiehMThaoKContiMGenetic dissection of epidermal growth factor receptor signaling during luteinizing hormone-induced oocyte maturationPLoS One201166e2157421738714
   PubMed Web of Science ®Google Scholar
• JamnongjitMGillAHammesSREpidermal growth factor receptor signaling is required for normal ovarian steroidogenesis and oocyte maturationProc Natl Acad Sci USA2005102 45162571626216260720
   PubMed Web of Science ®Google Scholar
• SalomonDSBrandtRCiardielloFNormannoNEpidermal growth factor-related peptides and their receptors in human malignanciesCrit Rev Oncol Hematol19951931832327612182
   PubMed Web of Science ®Google Scholar
• LafkyJMWilkenJABaronATMaihleNJClinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancerBiochim Biophys Acta20081785223226518291115
   PubMed Web of Science ®Google Scholar
• BartlettJMLangdonSPSimpsonBJThe prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancerBr J Cancer19967333013068562334
   PubMed Web of Science ®Google Scholar
• Fischer-ColbrieJWittAHeinzlHEGFR and steroid receptors in ovarian carcinoma: comparison with prognostic parameters and outcome of patientsAnticancer Res1997171B6136199066588
   PubMed Web of Science ®Google Scholar
• SkirnisdottirISorbeBSeidalTThe growth factors HER-2/neu and EGFR, their relationship, and their effects on the prognosis in early stage (FIGO I–II) epithelial ovarian carcinomaInt J Gynecol Cancer200111211912911328410
   PubMed Web of Science ®Google Scholar
• AlperOBergmann-LeitnerESBennettTAHackerNFStrombergKStetler-StevensonWGEpidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cellsJ Natl Cancer Inst200193181375138411562388
   PubMedGoogle Scholar
• LassusHSihtoHLeminenAGene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinomaJ Mol Med200684867168116607561
   PubMed Web of Science ®Google Scholar
• StadlmannSGuethUReiserUEpithelial growth factor receptor status in primary and recurrent ovarian cancerMod Pathol200619460761016554736
   PubMed Web of Science ®Google Scholar
• LeeCHHuntsmanDGCheangMCUAssessment of Her-1, Her-2, and Her-3 expression and Her-2 amplification in advanced stage ovarian carcinomaInt J Gynecol Pathol200524214715215782071
   PubMed Web of Science ®Google Scholar
• NielsenJSJakobsenEHølundBBertelsenKJakobsenAPrognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancerInt J Gynecol Cancer20041461086109615571614
   PubMed Web of Science ®Google Scholar
• MorishigeKIKurachiHAmemiyaKEvidence for the involvement of transforming growth factor α and epidermal growth factor receptor autocrine growth mechanism in primary human ovarian cancers in vitroCancer Res19915119532253281717146
   PubMed Web of Science ®Google Scholar
• TsujiokaHYotsumotoFShirotaKEmerging strategies for ErbB ligand-based targeted therapy for cancerAnticancer Res20103083107311220871027
   PubMed Web of Science ®Google Scholar
• CiardielloFTortoraGA novel approach in the treatment of cancer: targeting the epidermal growth factor receptorClin Cancer Res20017102958297011595683
   PubMed Web of Science ®Google Scholar
• ArteagaCLOverview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasiaSemin Oncol2002295 Suppl 143912422308
   PubMed Web of Science ®Google Scholar
• ArteagaCLThe epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasiaJ Clin Oncol200119Suppl 1832s40s11560969
   PubMed Web of Science ®Google Scholar
• NicholsonRIGeeJMHarperMEEGFR and cancer prognosisEur J Cancer200137 Suppl 4S9S1511597399
   PubMed Web of Science ®Google Scholar
• IlekisJVConnorJPPrinsGSFerrerKNiederbergerCScocciaBExpression of epidermal growth factor and androgen receptors in ovarian cancerGynecol Oncol19976622502549264571
   PubMed Web of Science ®Google Scholar
• OwensOJStewartCBrownILeakeREEpidermal growth factor receptors (EGFR) in human ovarian cancerBr J Cancer19916459079101931614
   PubMed Web of Science ®Google Scholar
• BerchuckARodriguezGCKamelAEpidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancerAm J Obstet Gynecol199116426696741992720
   PubMed Web of Science ®Google Scholar
• DimovaIZaharievaBRaitchevaSDimitrovRDoganovNTonchevaDTissue microarray analysis of EGFR and erbB2 copy number changes in ovarian tumorsInt J Gynecol Cancer200616114515116445625
   PubMed Web of Science ®Google Scholar
• LinCKChaoTKYuCPYuMHJinJSThe expression of six biomarkers in the four most common ovarian cancers: correlation with clinicopathological parametersAPMIS2009117316217519245589
   PubMed Web of Science ®Google Scholar
• BrustmannHEpidermal growth factor receptor expression in serous ovarian carcinoma: an immunohistochemical study with galectin-3 and cyclin D1 and outcomeInt J Gynecol Pathol200827338038918580315
   PubMed Web of Science ®Google Scholar
• TanakaYTeraiYTanabeAPrognostic effect of epidermal growth factor receptor gene mutations and the aberrant phosphorylation of Akt and ERK in ovarian cancerCancer Biol Ther2011111505721057220
   PubMed Web of Science ®Google Scholar
• AraújoAPRibeiroRPereiraDOvarian cancer and genetic susceptibility: association of A61G polymorphism in the EGF geneExp Biol Med20092343241245
   Web of Science ®Google Scholar
• GarciaAASillMWLankesHAA phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group studyGynecol Oncol2012124356957422037316
   PubMed Web of Science ®Google Scholar
• UllrichACoussensLHayflickJSHuman epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermal carcinoma cellsNature198430959684184256328312
   PubMed Web of Science ®Google Scholar
• PedersenMWMeltornMDamstrupLPoulsenHSThe type III epidermal growth factor receptor mutation, biological significance and potential target for anti-cancer therapyAnn Oncol200112674576011484948
   PubMed Web of Science ®Google Scholar
• ChuCTEverissKDWikstrandCJBatraSKKungHJBignerDDReceptor dimerization is not a factor in the signalling activity of a transforming variant epidermal growth factor receptor (EGFRvIII)Biochem J1997324Pt 38558619210410
   PubMed Web of Science ®Google Scholar
• MoscatelloDKHolgado-MadrugaMGodwinAKFrequent expression of a mutant epidermal growth factor receptor in multiple human tumorsCancer Res19955523553655397585629
   PubMed Web of Science ®Google Scholar
• SteffensenKDWaldstromMOlsenDAMutant epidermal growth factor receptor in benign, borderline, and malignant ovarian tumorsClin Cancer Res200814113278328218519753
   PubMed Web of Science ®Google Scholar
• PalayekarMJHerzogTJThe emerging role of epidermal growth factor receptor inhibitors in ovarian cancerInt J Gynecol Cancer200818587989018053062
   PubMed Web of Science ®Google Scholar
• IyerRBharhuarAA review of erlotinib – an oral selective epidermal growth factor receptor tyrosine kinase inhibitorExpert Opin Pharmacother201011231132020088749
   PubMed Web of Science ®Google Scholar
• GordonANFinklerNEdwardsRPEfficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter studyInt J Gynecol Cancer200515578579216174225
   PubMed Web of Science ®Google Scholar
• SirotnakFMZakowskiMFMillerVAScherHIKrisMGEfficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinaseClin Cancer Res20006124885489211156248
   PubMed Web of Science ®Google Scholar
• CullinaneCKleinschmidtMWebsterLKAntitumour activity of ZD1839 in combination with cisplatin in NIH 3T3 cells expressing human epidermal growth factor receptorProc Am Assoc Cancer Res200041482
   Google Scholar
• VaseyPAGoreMWilsonRA phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancersBr J Cancer200898111774178018506181
   PubMed Web of Science ®Google Scholar
• VaseyPAJaysonGCGordonAPhase III randomized trial of docetaxel-carboplatin versus paclitaxel carboplatin as first-line chemotherapy for ovarian carcinomaJ Natl Cancer Inst200496221682169115547181
   PubMed Web of Science ®Google Scholar
• BlankSVChristosPCurtinJPErlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: a phase II study based on surgical reassessmentGynecol Oncol2010119345145620837357
   PubMed Web of Science ®Google Scholar
• HirteHOzaASwenertonKA phase II study of erlotinib (OSI-774) given in combination with carboplatin in patients with recurrent epithelial ovarian cancerGynecol Oncol2010118330831220646751
   PubMed Web of Science ®Google Scholar
• NimeiriHSOzaAMMorganRJEfficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II ConsortiaGynecol Oncol20081101495518423560
   PubMed Web of Science ®Google Scholar
• ChambersSKClouserMCBakerAFOverexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancerClin Cancer Res201016215320532821041183
   PubMed Web of Science ®Google Scholar
• VergoteIBJolyFKatsarosDRandomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: A GCIG and EORTC-GCG studyJ Clin Oncol201230SupplLBA5000
   Web of Science ®Google Scholar
• MorgilloFBareschinoMABiancoRTortoraGCiardielloFPrimary and acquired resistance to anti-EGFR targeted drugs in cancer therapyDifferentiation200775978879917608727
   PubMed Web of Science ®Google Scholar
• BiancoRDamianoVGelardiTDanieleGCiardielloFTortoraGRational combination of targeted therapies as a strategy to overcome the mechanisms of resistance to inhibitors of EGFR signalingCurr Pharm Des200713333358336718045190
   PubMed Web of Science ®Google Scholar
• WeihuaZTsanRHuangWCSurvival of cancer cells is maintained by EGFR independent of its kinase activityCancer Cell200813538539318455122
   PubMed Web of Science ®Google Scholar
• KrysanKLeeJMDohadwalaMInflammation, epithelial to mesenchymal transition, and epidermal growth factor receptor tyrosine kinase inhibitor resistanceJ Thorac Oncol20083210711018303428
   PubMed Web of Science ®Google Scholar
• MorelliMPCasconeTTroianiTSequence dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitorsAnn Oncol200516Suppl 4iv61iv6815923432
   PubMed Web of Science ®Google Scholar
• BastRCHennessyBMillsGBThe biology of ovarian cancer: new opportunities for translationNat Rev Cancer20099641542819461667
   PubMed Web of Science ®Google Scholar
• YapTACardenCPKayeSBBeyond chemotherapy: targeted therapies in ovarian cancerNat Rev Cancer20099316718119238149
   PubMed Web of Science ®Google Scholar
• SampsonJHAkabaniGArcherGEIntracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumorsNeuro Oncol200810332032918403491
   PubMed Web of Science ®Google Scholar